Figure 6.
LMP400 and Niraparib offer improved bioavailability than current analogs. (A) Comparison of survival of HEK293 cells stably expressing common ATP-Binding Cassette (ABC) transporters upon treatment with LMP400, Topotecan, or SN-38. (B) Comparison of survival of HEK293 cells stably expressing common ABC transporters upon treatment with Niraparib or Olaparib.

LMP400 and Niraparib offer improved bioavailability than current analogs. (A) Comparison of survival of HEK293 cells stably expressing common ATP-Binding Cassette (ABC) transporters upon treatment with LMP400, Topotecan, or SN-38. (B) Comparison of survival of HEK293 cells stably expressing common ABC transporters upon treatment with Niraparib or Olaparib.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close